HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Unveils Plan To Boost Transparency To Industry

This article was originally published in The Rose Sheet

Executive Summary

FDA has identified 19 steps to improve its communications with drug and medical device manufacturers, promising quicker responses to industry questions.

You may also be interested in...



FDA Should Broaden Consumer Access To Compliance Info – Task Force

FDA’s transparency task force proposes a multi-pronged approach to make the agency’s compliance and enforcement data more accessible and user-friendly online.

FDA Should Broaden Consumer Access To Compliance Info – Task Force

FDA’s transparency task force proposes a multi-pronged approach to make the agency’s compliance and enforcement data more accessible and user-friendly online.

Taylor Is Sharfstein's Temporary Replacement As FDA's Second-In-Command

John Taylor, counselor to FDA Commissioner Margaret Hamburg, will serve temporarily as second-in-command while Hamburg considers how to reorganize the agency's leadership following Principal Deputy Commissioner Joshua Sharfstein's departure.

Related Content

UsernamePublicRestriction

Register

RS017394

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel